Loading…
Chinese maker of antibiotic active pharmaceutical ingredients, used in both human and animal-health medicines.
Chinese maker of antibiotic active pharmaceutical ingredients, used in both human and animal-health medicines.
Moat: narrow (scale, regulatory licence). Scale antibiotic API production with environmental/regulatory compliance built up over years.
Headquarters: China · Employees: 4,251
Size Guobang Pharma (605507.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.84B, the 1364th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.71 on 6 Nov 2026.
Performance Over six months the shares fell 8.1%, against -10.6% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 3.2% over the last twelve months (peer median +11.4%); the operating margin is 12.2% (peer median 19.4%).
Valuation It trades at 15.9× forward earnings against a peer median of 24.4× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.13B | CN¥5.99B | CN¥5.87B | CN¥5.34B | CN¥5.70B |
| Revenue growth | — | +2% | +10% | -6% | — |
| Gross profit | CN¥1.73B | CN¥1.46B | CN¥1.37B | CN¥1.17B | CN¥1.49B |
| EBITDA | n/a | CN¥1.39B | CN¥1.27B | CN¥949M | CN¥1.21B |
| Net income | CN¥622M | CN¥821M | CN¥782M | CN¥612M | CN¥921M |
| Free cash flow | CN¥569M | CN¥282M | CN¥287M | -CN¥232M | CN¥214M |
| Capital expenditure | CN¥360M | CN¥278M | CN¥419M | CN¥748M | CN¥803M |
| Total debt | CN¥2.01B | CN¥1.66B | CN¥1.99B | CN¥2.06B | CN¥1.21B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guobang Pharma 605507.SS | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% |
| Harbin Pharmaceutical 600664.SS | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 605507.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.2% | +0.6% | 4th lowest of 21 |
| 6-month return | -8.1% | -10.6% | 10th highest of 21 |
| Distance from 52-week high | -26.6% | -27.8% | 10th highest of 21 |
| Revenue growth (TTM) | +3.2% | +11.4% | 6th lowest of 21 |
| Operating margin | 12.2% | 19.4% | 10th lowest of 21 |
| Forward P/E | 15.9× | 24.4× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -5.8% | 11.2% | 4th least demanding of 14 |
| Growth delivered (Del g) | +7.4% | +15.7% | 6th lowest of 14 |
| Hurdle (Req g minus delivered) | -13.2 pp | -0.4 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +5.4 pp | +0.4 pp | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.88B | -13% | -6% | 8% | 22.5× | 0.1% | +0.5% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |